TOP > 外国特許検索 > ONCOLYTIC VIRUS (ONCOLYTIC IMMUNOTHERAPY) CAPABLE OF EFFECTIVELY TREATING EVEN METASTATIC CANCER WHILE ENSURING SAFETY, WITH EXPRESSION CONTROL SYSTEM PROVIDING OPTIMAL EXPRESSION LEVEL OF MOUNTED IMMUNOGENIC GENE

ONCOLYTIC VIRUS (ONCOLYTIC IMMUNOTHERAPY) CAPABLE OF EFFECTIVELY TREATING EVEN METASTATIC CANCER WHILE ENSURING SAFETY, WITH EXPRESSION CONTROL SYSTEM PROVIDING OPTIMAL EXPRESSION LEVEL OF MOUNTED IMMUNOGENIC GENE NEW

外国特許コード F190009981
整理番号 (S2018-0284-N0)
掲載日 2019年10月28日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2018JP041541
国際公開番号 WO 2019093435
国際出願日 平成30年11月8日(2018.11.8)
国際公開日 令和元年5月16日(2019.5.16)
優先権データ
  • 特願2017-215579 (2017.11.8) JP
  • 特願2018-050722 (2018.3.19) JP
発明の名称 (英語) ONCOLYTIC VIRUS (ONCOLYTIC IMMUNOTHERAPY) CAPABLE OF EFFECTIVELY TREATING EVEN METASTATIC CANCER WHILE ENSURING SAFETY, WITH EXPRESSION CONTROL SYSTEM PROVIDING OPTIMAL EXPRESSION LEVEL OF MOUNTED IMMUNOGENIC GENE NEW
発明の概要(英語) A purpose of the present invention is to develop an immuno-viral therapy vector that has an optimal therapeutic effect while ensuring a high degree of safety, on the basis of the novel concept of finding the optimal expression level of a therapeutic gene to bring about the maximum therapeutic effect with no side effects. The present invention provides an oncolytic virus or similar that is characterized by having an immunogenic gene that is functionally linked downstream of an E2F promoter or a promoter demonstrating the same activity as an E2F promoter, wherein a promoter of nucleic acids coding for at least one factor that is essential for virus replication or assembly is substituted with a promoter of a factor for which expression is organ-specifically enhanced, or a promoter of a factor for which expression is cancer cell-specifically enhanced.
従来技術、競合技術の概要(英語) BACKGROUND ART
' Specific cancer cells and genes that show the growth of the virus killing effect of recombinant virus' tumor immune to virus induced gene-mounted (Oncolytic virus) tumor immune therapy (Oncolytic immunotherapy) is soluble, in the year 2015 in Europe and is mounted on the cytokine genes (Amgen Inc. T-Vec) First-in-class is a pharmaceutical as approved (breakthrough pharmaceutical) as, the innovative worldwide as a cancer therapeutic agents is expected to be the most promising candidate (Non-Patent Document 1-and Non-Patent Document 3).
The inventors of the present invention, in the dawn of gene therapy to 1990 year period, by the introduction of immunization the virus non-proliferation, immune gene therapy methods developed prior to the world (non-patent document 4-6). Then, an article of the many gene therapy as published its own research and development over many years has been performed.
On the other hand, the inventors of the present invention, this is one of the tumor lytic viruses (Conditionally replicating adenovirus) for Quantum proliferation, growth control unit of the virus, gene therapy, one of the viral properties of the modified element 3, a high degree of cancer cell-specific multi-factor controlling the growth of the virus to ensure safety, the therapeutic gene can be introduced to enhance the therapeutic effect, and the adenovirus proliferation of next generation, ' a type m-CRA-growth control factor (Conditionally replicating adenovirus regulated with multiple-tumor specific factors) developed for the preparation of the efficient (non-patent document 7, Patent Document 1). Adenovirus genome size in the medium of the 30-40kb virus recombinant although it is not easy, and a type different from the non-growth, proliferation and standard efficiency of a type does not exist even a technology. Therefore, a plurality of locations with highly engineered m-CRA development and, a plurality of candidate m-CRA and screening to compare experimental study has been developed. Therefore the present inventors have developed a technique by first m-CRA, this technique makes it possible to prepare only a number of candidate m-CRA to verify and search, and the competing technology is far in over the tumor virus pharmaceutical performance m-CRA has been developed a medicament. Of the basic skeleton of the first and m-CRA, viral growth of the control unit as in the tumor-specific promoter, and the present invention may also be used to control the viral growth gene promoter of survivin reactive survivin (Surv.m-CRA) m-CRA, or viral gene promoter of growth control method according to the method according to (Patent Document 2) reactive m-CRA was developed. Surv.m-CRA is, until this best competing technology (Tert promoter virus propagated CRA; basic skeleton of the same type of clinical tests good results have been issued for this to the best one of the competing technology; Non-Patent Document 8) on both sides of the safety and therapeutic effect than the (non-patent document 9) that is excellent in superiority of the competing technology to, an existing treatment technique (the anti-cancer agent, radiation therapy) may be a cancer stem cell is invalid (non-patent document 10) can be treated effectively to the superiority of the prior art. 'Is not mounted at the therapeutic gene' Surv.m-CRA Surv.m-CRA-1 to designated, this is confirmed that the safety is also a clinical trial, the current, the inventors have found that human cancer patients in the clinical trial doctor and the main person, confirms a favorable result even a human being. Cancer cells Surv.m-CRA-1 only specifically binds to, the virus can be grown with high efficiency, the amplified viral protein specific for cancer cells and effectively treat (safety), a therapeutic agent in the tumor virus.
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • KAGOSHIMA UNIVERSITY
  • 発明者(英語)
  • KOSAI, Ken-ichiro
  • IJICHI Nobuhiro
国際特許分類(IPC)
指定国 National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DJ DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JO JP KE KG KH KN KP KR KW KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG
特許の内容に興味を持たれた方、ライセンスをご希望の方は、下記「問合せ先」までお問い合わせください。

PAGE TOP

close
close
close
close
close
close